大和:舜宇(2382.HK)為大中華區手機板塊的首選 予“買入”評級
大和發佈報告稱,舜宇光學(02382)公佈上月出貨量,手機鏡頭模組(HCM)同比升1%,手機鏡頭(HLS)同比升44%及車載鏡頭(VLS)同比升32%,前兩者出貨量較預期佳,後者則符合預期。該行預計,舜宇2019-20年盈利有34-38%的強勁增長。
該行表示,雖然舜宇主要的攝像頭模組及鏡頭供應商為華為,雖因國際貿易局勢不明,但該行不改長遠對舜宇正面開好的看法,予“買入”投資評級,並指舜宇為大中華區手機板塊的首選股份。
另外,該行預期舜宇今年下半年的經營利潤率擴張至12%,2020年則達12.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.